Teresa Vitali's questions to Alnylam Pharmaceuticals Inc (ALNY) leadership • Q1 2025
Question
Teresa Vitali, on for Greg Harrison, asked how Alnylam is leveraging its commercial expertise and what specific strategies are being employed to capture patients switching from tafamidis.
Answer
Chief Commercial Officer Tolga Tanguler explained that AMVUTTRA's distinct mechanism of action and compelling HELIOS-B data, where nearly half of patients were already on a stabilizer, position it as a clear first-line option. He added that for patients progressing on stabilizers, AMVUTTRA is a very important treatment option, and the company is already seeing uptake in this switch population.